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Vascular endothelial growth factor (VEGF) is a potent angiogenic inducer that stimulates the expression of
tissue factor (TF), the major cellular initiator of blood coagulation. Here we show that signaling triggered by
VEGF induced DNA-binding and transcriptional activities of nuclear factor of activated T cells (NFAT) and
AP-1 in human umbilical vein endothelial cells (HUVECs). VEGF also induced TF mRNA expression and gene
promoter activation by a cyclosporin A (CsA)-sensitive mechanism. As in lymphoid cells, NFAT was dephos-
phorylated and translocated to the nucleus upon activation of HUVECs, and these processes were blocked by
CsA. NFAT was involved in the VEGF-mediated TF promoter activation as evidenced by cotransfection
experiments with a dominant negative version of NFAT and site-directed mutagenesis of a newly identified
NFAT site within the TF promoter that overlaps with a previously identified kB-like site. Strikingly, this site
bound exclusively NFAT not only from nuclear extracts of HUVECs activated by VEGF, a stimulus that failed
to induce NF-kB-binding activity, but also from extracts of cells activated with phorbol esters and calcium
ionophore, a combination of stimuli that triggered the simultaneous activation of NFAT and NF-kB. These
results implicate NFAT in the regulation of endothelial genes by physiological means and shed light on the
mechanisms that switch on the gene expression program induced by VEGF and those regulating TF gene
expression.
Angiogenesis, the sprouting of new capillaries from preex-
isting vascular beds, is a multistep program that involves the
activation, proliferation, and migration of endothelial cells.
Vascular endothelial growth factor (VEGF) is a potent angio-
genic inducer that has been implicated in physiological and
physiopathological conditions associated with angiogenesis
(19). Thus, VEGF plays a major role in vasculogenesis and
angiogenesis during embryonic development (6, 18), and en-
hanced expression of VEGF has been detected in processes
associated with the menstrual cycle, pregnancy, rheumatoid
arthritis, wound healing, diabetic retinopathy, and atheroscle-
rosis (4, 19). In addition, there is considerable evidence to
support a critical role of VEGF in tumorigenesis, which may be
related to the neovascularization required for tumor growth
and dissemination. Thus, VEGF mRNA is significantly en-
hanced in most tumors analyzed so far, and multiple cell lines
have been found to synthesize and secrete VEGF. Further-
more, anti-VEGF antibodies inhibit the growth of tumors in
vivo (4, 27, 63).
VEGF displays a potent mitogenic activity for endothelial
cells and increases endothelial-cell permeability and migration
(19). The biological effects of VEGF on endothelial cells are
exerted through its binding to Flt-1 and Flk-1/KDR, two high-
affinity tyrosine kinase receptors, both of which are related to
the platelet-derived growth factor receptors (16, 40, 48). Sig-
naling through such receptors initiates the activation of the
intracellular signal transduction cascades that switch on the
expression of genes that control the specific response to
VEGF. Thus, VEGF induces the expression of the plasmino-
gen activators (PA) uPA and tPA, the urokinase receptor
(uPAR), and the metalloproteinase interstitial collagenase, fa-
cilitating the extracellular matrix degradation and further mi-
gration and sprouting of endothelial cells (19). VEGF also
induces the expression of tissue factor (TF) (9), a glycoprotein
expressed by monocytes and endothelial cells that functions as
the high-affinity receptor and cofactor for the coagulation fac-
tors VII/VIIa and is the main initiator of the extrinsic pathway
of the coagulation cascade. The induction of TF expression on
the surface of monocytes and endothelial cells is upregulated
upon activation with a number of stimuli including the proin-
flammatory cytokines tumor necrosis factor alpha (TNF-a)
and interleukin-1b (IL-1b), the bacterial lipopolysaccharide
(LPS), phorbol esters, and thrombin, as well as VEGF (34). TF
is thought to play a major role in thrombogenic disorders in the
setting of inflammation, septic shock, or cancer (34, 35, 52).
Besides these properties, the targeted disruption of TF results
in embryonic death due to a defective yolk sac vessel and
abnormal vitelloembryonic circulation (7), a phenotype that in
part resembles that found in VEGF-deficient embryos (6, 18).
Although many reports have addressed the biological re-
sponses of endothelial cells to VEGF, the intracellular trans-
duction pathways that connect the signals between the cell
membrane receptors and the nucleus, as well as the transcrip-
tion factors that couple such signaling to the expression of the
genes that regulate the cellular response to VEGF, are begin-
ning to be understood. In this regard, a number of intracellular
signaling components targeted by VEGF have been recently
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identified in different cell systems. VEGF induces tyrosine
phosphorylation of molecules containing SH2 domains as well
as other signaling molecules including phospholipase Cg, phos-
phatidylinositol 3-kinase, GTPase-activating protein, p125FAK,
paxillin, and the adapter proteins Nck and shc (1, 12, 21, 28, 56,
62). In addition, a number of recent reports have implicated
VEGF in the activation of different members of the family of
mitogen-activated protein kinases (MAPKs) including the ex-
tracellular signal-regulated kinases (ERKs), the stress-acti-
vated protein kinases/c-jun N-terminal kinases (SAPKs/JNKs),
and the p38/HOG kinase (1, 12, 28, 30, 53, 56).
In accordance with a functional activation of phospholipase
Cg, VEGF has also been reported to induce turnover of ino-
sitol phosphates, diacylglycerol production, and elevation of
intracellular Ca21 concentrations (3, 45, 67). In different cell
types, calcium signals lead to the activation of NFAT proteins,
a family of transcription factors composed of at least four
structurally related members, NFATp (NFAT1), NFATc
(NFAT2), NFAT3, and NFAT4 (51). Calcineurin, a Ca21/
calmodulin-dependent phosphatase, regulates the processes of
dephosphorylation and nuclear import of NFAT, both of which
are blocked by the immunosuppressive drugs cyclosporin A
(CsA) and FK506 (58, 59). Once in the nucleus, NFAT pro-
teins can cooperate with transcription factors of the Fos and
Jun families to regulate the inducible expression of a number
of genes involved in the regulation and function of the immune
response (50). Thus, NFAT proteins have been involved in the
regulation of the gene expression of IL-2, IL-4, granulocyte-
macrophage colony-stimulating factor (GM-CSF), TNF-a, or
CD40 and Fas ligands (11, 51). Recently, NFATp has been
found in endothelial cells, where it participates in the inducible
expression of the GM-CSF gene in response to pharmacolog-
ical activation by phorbol myristate acetate (PMA) plus Ca21
ionophore (10). In addition, during embriogenesis NFATc is
expressed in the endocardium, a highly specialized endothe-
lium that is involved in the morphogenesis of cardiac valves
and septum, which are not developed in mice bearing a tar-
geted disruption in the NFATc gene (13, 49). However, a
functional role of NFAT proteins regulating the expression of
endothelial genes in response to physiological stimuli has not
yet been addressed.
Because of the involvement of MAPK cascades and in-
creases in the intracellular calcium concentration in the signal-
ing induced by VEGF, we here analyzed the role of NFAT and
AP-1 in the activation of primary human endothelial cells by
VEGF. We show that in human umbilical vein endothelial cells
(HUVECs), VEGF triggers the dephosphorylation, transloca-
tion, and transcriptional activity of NFATp, which is accom-
panied by AP-1 activation. Further analysis involved NFAT in
the regulation of the TF gene expression induced by VEGF.
These results provide information on the mechanisms that
mediate the gene expression program induced by VEGF and
involve the transcription factors NFAT and AP-1 in the regu-
lation of the expression of endothelial genes by physiological
means. Moreover, the inhibitory effects of CsA on TF gene
expression may be related to the beneficial effects displayed by
this drug in pathological processes associated with a deregula-
tion of TF expression.
MATERIALS AND METHODS
Cell culture and reagents. Human umbilical vein endothelial cells (HUVECs)
were isolated from umbilical veins as previously described (42) and routinely
grown on 0.5% gelatin-coated tissue culture flasks in medium 199 (Biowhittaker)
supplemented with 20% fetal calf serum (FCS), 50 mg of bovine brain extract per
ml, and 100 mg of heparin per ml. The cells were used between passages 6 and
10. Jurkat cells were maintained in RPMI 1640 medium (Gibco-BRL) supple-
mented with 10% FCS. The recombinant human VEGF165 was purchased from
Peprotech EC Ltd., (London, United Kingdom) or provided by H. Riese and I.
Prieto (Pharmacia-Upjohn, Madrid, Spain). CsA was from Sandoz. TNF-a
(3.2 3 107 U/mg) was from Wichem (Vienna, Austria). PMA, the calcium
ionophore A23187, and actinomycin D were from Sigma Chemical Co. (St.
Louis, Mo).
Immunofluorescence experiments. HUVECs grown on 1% gelatin-coated cov-
erslips in 24-well tissue culture plates were either left untreated or incubated for
2 h with CsA (200 ng/ml) before stimulation with VEGF (50 ng/ml), Ca21
ionophore (1 mM), or TNF-a (25 ng/ml) for 20 min. The cells were then fixed
with 3% paraformaldehyde in phosphate-buffered saline (PBS) for 15 min at
room temperature and washed three times (5 min each) with washing buffer
(PBS, 0.01% [vol/vol] Nonidet P-40 [NP-40]). After blocking for 30 min at 37°C
with TNB buffer (0.1 M Tris-HCl [pH 7.5], 0.15 M NaCl, 0.5% blocking reagent
[Boehringer Mannheim]), the coverslips were incubated for 45 min at 37°C with
the anti-NFATp monospecific antiserum 67.1 (22) (0.01% [vol/vol] in TNB),
provided by Anjana Rao. Unbound antibody was removed by rinsing twice with
washing buffer (5 min at room temperature), and the coverslips were incubated
for 20 min at 37°C with a fluorescein-conjugated anti-rabbit immunoglobulin (Ig;
Amersham) (0.1% [vol/vol] in TNB), washed twice, and mounted in Mowiol
mountant on glass slides. The cells were visualized with a Nikon Labophot-2
photomicroscope.
Subcellular fractionation and Western blot analysis. After the different treat-
ments, confluent HUVECs grown in 35-mm culture dishes (one dish per condi-
tion) were washed with cold PBS and lysed in 100 ml of hypotonic buffer (10 mM
Tris-HCl [pH 7.5] containing 10 mM NaCl, 3 mM MgCl2, 1 mM phenylmethyl-
sulfonyl fluoride, 0.5 mM dithiothreitol [DTT], 0.1 mM EGTA, 2 mM leupeptin,
1 mg of aprotinin per ml, and 0.05% NP-40). The supernatant containing the
cytosolic extracts was removed and resuspended in Laemmli buffer, and the
nuclei were washed twice in hypotonic buffer without detergent and resuspended
in Laemmli buffer. Whole-cell extracts from Jurkat cells were prepared by direct
lysis in Laemmli buffer of PBS-washed cells collected after centrifugation. To
determine the effect of RNA synthesis inhibition on the nuclear export of
NFATp, HUVECs were pretreated with actinomycin D (5 mg/ml) for 4 h,
washed, and lysed 5 min, 1 h, and 4 h after activation with VEGF.
The different extracts were boiled and resolved, under reducing conditions, by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (6 or 12% polyacryl-
amide) for NFATp or proliferating-cell nuclear antigen detection, respectively.
The gels were transferred to nitrocellulose membranes and blocked with a 5%
(wt/vol) skim milk solution in Tris-buffered saline (TBS) buffer at 4°C overnight.
After being washed twice in TBS-T (TBS, 0.05% Tween 20), the membranes
were incubated for 2 h at room temperature with 0.03% or 0.01% (vol/vol) 67.1
and anti-PCNA (clone PC10; Dako) monoclonal antibody (64), respectively, in
TBS-T. The membranes were washed five times for 5 min in TBS-T, incubated
for 2 h at room temperature with the corresponding secondary antibody (per-
oxidase-labeled goat anti-rabbit IgG or anti-mouse IgG plus IgM [Pierce]),
washed three times with TBS-T, and briefly rinsed in distilled H2O. Bound
antibodies were detected with the ECL Western blotting analysis kit (Amer-
sham).
Nuclear extracts and EMSAs. For nuclear protein extraction, attached
HUVECs grown in 150-mm dishes were lysed with 2 ml of hypotonic buffer
containing 0.05% NP-40 (described above), except that 0.75 mM spermidine,
0.15 mM spermine, 10 mM Na2MoO4, and pepstatin (1 mg/ml) were also in-
cluded. Nuclei were detached from the plates, collected, incubated in buffer C
(20 mM HEPES [pH 7.6], 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT,
0.5 mM phenylmethylsulfonyl fluoride, 10 mM Na2MoO4, 1 mg of pepstatin per
ml, 4 mg of leupeptin per ml, 4 mg of aprotinin per ml) for 30 min in a rocking
platform, and centrifuged at 15,000 3 g for 10 min and the supernatants, con-
taining the nuclear extracts, were frozen immediately in liquid nitrogen and
stored at 280°C. The protein concentration was quantified by the Bradford
procedure.
Electrophoretic mobility shift assays (EMSAs) were performed by incubating
the nuclear proteins (1.5 to 2 mg) with 1 mg of poly(dI-dC) and 4 ml of 53 DNA
binding buffer (10% [wt/vol] polivinylethanol, 12.5% [vol/vol] glycerol, 50 mM
Tris [pH 8], 2.5 mM EDTA, 2.5 mM DTT) in a final volume of 18 ml on ice for
10 min. Then 2 ml (1 ng/ml) of 32P-labeled double-stranded oligonucleotide (5 3
107 to 1 3 108 cpm/mg), was added to the reaction mixture, which was incubated
at 4°C for an additional 30 min. For competition experiments, a 30-fold molar
excess of unlabeled oligonucleotide was added before the addition of the probe.
When indicated, nuclear extracts were incubated with 0.5 ml of either a preim-
mune serum, the anti-NFATp antiserum 67.1, or the 796 anti-all NFAT anti-
serum (33) or with 1 ml of the antiserum 1226 raised against the p65 NF-kB
subunit. Antisera were incubated for 15 min at 4°C before the addition of the
probe. DNA-protein complexes were resolved by electrophoresis in 4% nonde-
naturing polyacrylamide gels. The sequences of the oligonucleotides (59 to 39)
used in these experiments were as follows: gatcATAAAATTTTCCAATGTA
AAC (mouse NFAT P sequence 260 to 280 of the murine IL-4 promoter),
gatcGTAGACCGTGATTCAAGCTTAGC (human AP-1 2284 site of the
ICAM-1 promoter), gatcGGGATTTCACCT (NF-kB-binding site of the human
IL-2 promoter), ctagCCGGAGTTTCCTACC (nucleotides 2183 to 2197 of the
human TF promoter [positions 2186 to 2191 boldface]), ctagCCGGAGGAAT
TCACC (nucleotides 2183 to 2197 of the human TF promoter containing
mutated bases at positions 2186 to 2191 [boldface]), and AGTTGAGGGGA
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CTTTCCCAGGC (oligonucleotide including the prototypic NF-kB site of the
murine k light-chain enhancer).
Plasmid constructs and transient-transfection assays. The luciferase reporter
plasmid NFAT-Luc, containing three tandem copies of the distal NFAT-binding
site of the IL-2 gene promoter coupled to the IL-2 minimal promoter, and the
pSH102CD418 NFATc expression plasmid, a derivative of plasmid pBJ5 that
encodes a dominant negative truncated version of NFAT, have been previously
described (17, 43) and were provided by G. Crabtree. The reporter plasmids pL1
(22106 to 1121) and pL4 (2278 to 1121), containing deletion fragments of the
TF promoter inserted into the cloning site of the p19luc luciferase vector (37),
were provided by N. Mackman. The pCMV-TAM67, a derivative of pCMV
plasmid that encodes a c-Jun dominant negative version (47), was a gift from
C. M. Zacharchuk. The AP-1-dependent reporter plasmid 273 Col Luc contain-
ing the 273 to 163 region of the human collagenase promoter coupled to the
luciferase gene (15) was provided by M. Karin. The AP-1-dependent luciferase
construct driven by the 236 to 137 rat prolactin minimal promoter under the
control of four tandem copies of the TPA-responsive element (TRE) consensus
motif TGACTCA (AP-1 PROL Luc) and the parental vector (PROL Luc) were
provided by M. Rinco´n.
For transient-transfection experiments, HUVECs were plated in 100-mm tis-
sue culture dishes (1.5 3 106 cells/plate) the day before transfection. The cells
were transfected in 4 ml of Dulbecco’s minimal essential medium plus 0.5% FCS
using 10 mg of the indicated luciferase reporter plasmids, by the calcium phos-
phate procedure as previously described (42). Briefly, HUVECs were incubated
with precipitated DNA for 4.5 h, washed twice with PBS, and detached with
trypsin from the 100-mm plates. After centrifugation (1,200 rpm for 5 min in a
Sorvall H1000B rotor), the cells were resuspended in OPTI-MEM (Life Tech-
nologies) supplemented with 0.5% FCS and split among six-well (35-mm) tissue
culture plates (2.5 35-mm dishes were plated from one 100-mm plate) precoated
with 0.5% of gelatin. Transfected cells were incubated at 37°C for 16 h and
exposed to different stimuli for an additional 6 h unless otherwise specified. Then
the cells were lysed and luciferase activity was measured in a Lumat LB 9501
luminometer (Berthold, Wildbad, Germany) as specified in the instructions of a
Luciferase system kit (Promega). In cotransfection experiments, 5 mg of pBJ5
and pSH102CD418 or 1.7 mg of pCMV-TAM67 and pCMV-b-galactosidase
expression plasmids were coprecipitated together with the reporter vector.
Transfection experiments were performed in triplicate. The data presented are
expressed as the mean and standard deviation of the determinations performed
in triplicate. A representative experiment is shown in the reporter assays in all
cases. The expression of Renilla luciferase was used as an internal control to
normalize the values obtained with the firefly luciferase constructs. A total of 0.5
mg of the Renilla luciferase expression vector pRLCMV (Promega) was used in
cotransfection experiments. In these experiments, 1/10 of cells cotransfected with
both types of luciferase plasmids were plated in 24-well tissue culture plates,
incubated at 37°C for 24 h, and lysed with passive lysis buffer. Renilla luciferase
activity was measured by using the Dual luciferase assay kit (Promega), as
specified by the manufacturer, to discriminate the activity of the two types of
luciferases.
Northern blot analysis. After different treatments, total RNA was isolated
from attached HUVECs by using the Ultraspect system (Biotecx Laboratories,
Inc.). Denatured RNA (20 mg per sample) was electrophoresed on 1% formal-
dehyde–agarose gels and blotted onto a nitrocellulose membrane. After UV
cross-linking, the membranes were hybridized overnight at 42°C with specific
probes. A tissue factor probe spanning positions 95 to 925 of the TF cDNA was
generated by PCR and cloned into the pCR2.1 plasmid (Invitrogen) by using the
oligonucleotides and conditions previously reported for this purpose (23). The
resulting plasmid was digested with EcoRI and the fragment of the TF cDNA
from 95 to 853 was used as a probe. For c-fos and c-jun mRNA detection, the
0.8-kb BglII-NcoI fragment of the c-fos cDNA and a 0.8-kb HindIII-PstI fragment
of c-jun cDNA were used.
Site-directed mutagenesis. Mutation of the NFAT binding site localized at
positions 2186 to 2194 of the TF promoter was performed by PCR with the pL4
plasmid as a template. Primer pL4 HindIII sense (59 tttaagcttGGGCAACTAG
ACCCGCCTGC) and pL4 EcoRI antisense (59 tttgaattcCTCCGGGACCCTG
CAAGGG 39) were used to generate PCR fragment A. Primer Mut EcoRI sense
(59 tttgaattcACCGGGAGGAGGCGGGGC) and TF XmaI antisense (59 CCG
GCCCGGGTCACTTGCC) were used to generate fragment B. Fragments A
and B were subjected to 35 cycles of amplification with the following thermal
cycle: 94°C for 30 s, 64°C for 30 s, and 72°C for 90 s. Primers pL4 EcoRI antisense
and Mut EcoRI sense were partially complementary and carried point mutations
that transform the NFAT core-binding site into an EcoRI restriction site. PCR
fragments A and B were digested with HindIII and EcoRI or with EcoRI and
XmaI, respectively, and the resulting fragments were ligated into the
HindIII-XmaI-digested pL4 vector to generate the pL4 mut (2186 to 2194)
plasmid. The nucleotide sequence of the mutant was confirmed by DNA
sequencing.
RESULTS
VEGF triggers NFATp dephosphorylation and nuclear
translocation in HUVECs by a CsA-sensitive mechanism. To
determine whether NFAT could mediate transcriptional re-
sponses in endothelial cells stimulated with VEGF, we first
performed immunocytochemical analysis with HUVECs by us-
ing a specific anti-NFAT1/NFATp antiserum. As shown in Fig.
1A, endogenous NFATp was present in the cytoplasm of rest-
ing cells and translocated to the nucleus upon activation with
calcium ionophore. Strikingly, stimulation by VEGF also re-
sulted in complete translocation of NFATp to the nucleus
whereas TNF-a failed to modify the cytoplasmic localization of
the transcription factor. Furthermore, preincubation with
pharmacological concentrations of CsA resulted in the total
prevention of the nuclear translocation of NFATp triggered by
both VEGF or calcium ionophore (Fig. 1A, bottom panels).
Since, CsA targets the phosphatase activity of calcineurin,
precluding the dephosphorylation and translocation of NFAT,
in other cell systems (29, 55), we designed Western blot exper-
iments to analyze the phosphorylation status of NFAT in frac-
tionated cellular extracts prepared at different time points after
activation with VEGF. These experiments revealed that expo-
sure of HUVECs to VEGF induced a rapid dephosphorylation
and nuclear translocation of NFATp that was complete as
early as 5 min upon activation. Although dephosphorylated
NFATp was present in the nucleus for at least 2 h, after 20 min
of treatment the presence in the nucleus of phosphorylated
NFATp was already evident and the amount of nuclear
NFATp was declining to undetectable levels by 4 h. Con-
versely, phosphorylated NFATp was progressively reappearing
in the cytosolic fractions to reach maximal levels by 2 to 4 h
(Fig. 1B). The dephosphorylation, nuclear translocation, and
further expression of NFATp in the cytoplasm of VEGF-
treated cells were also observed when the RNA synthesis of
HUVECs was inhibited by actinomycin D (data not shown).
Parallel Western blot analysis indicated that both the dephos-
phorylation and nuclear translocation of NFATp induced by
either VEGF or calcium ionophore were prevented by CsA
(Fig. 1C). Control experiments showed that the upper and
lower bands of NFATp detected in HUVECs displayed iden-
tical mobility to that of the phosphorylated and dephosphory-
lated NFATp forms (data not shown) previously characterized
in T cells (33, 39, 46). In addition, the subcellular fractionation
process of the extracts used to analyze the import and export of
NFATp was controlled by Western blots that revealed the
presence of the proliferating-cell nuclear antigen (64) in nu-
clear extracts but not in the cytosolic fractions of VEGF-
treated cells (Fig. 1D). These results, on the one hand, suggest
that NFATp imported to the nucleus is rapidly phosphorylated
and further exported to the cytoplasm after 1 to 2 h of activa-
tion with VEGF and, on the other hand, indicate that the
dephosphorylation and translocation of NFATp in endothelial
cells were sensitive to the calcineurin inhibitor CsA. Therefore,
the nuclear import and export of NFATp induced by VEGF in
endothelial cells appears to be regulated in a similar fashion to
that demonstrated for lymphocytes activated by different stim-
uli.
VEGF induces NFAT DNA-binding activity. We further an-
alyzed the effect of VEGF on the activation of NFAT by
determining the binding of the transcription factor to an
NFAT site of the IL-4 promoter that has been shown to bind
NFAT independently of AP-1 transcription factor (65). In
agreement with the results of the Western blot experiments,
EMSAs with nuclear extracts from HUVECs exposed to
VEGF for different periods showed that NFAT-binding activ-
ity was significantly induced as early as 5 min and was maximal
after 20 min of treatment. High levels of binding were still
found after 60 min of treatment and markedly declined by 4 h
(Fig. 2A). Similarly, pharmacological activation of HUVECs
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FIG. 1. VEGF induces dephosphorylation and nuclear localization of NFATp in HUVECs. (A) Immunocytochemical staining of HUVECs unstimulated (2) or treated
with VEGF (50 ng/ml), the calcium ionophore A23187 (1 mM) (I0), or 25 ng of TNF-a per ml for 20 min. The cells were either untreated (top panels) or incubated with 200
ng of CsA per ml (bottom panels) for 2 h prior to the addition of the stimuli. After stimulation, the cells were fixed and stained with the anti-NFATp antiserum 67.1. (B and
C) HUVECs, either pretreated or not (2) with CsA (200 ng/ml) for 2 h, were left untreated (2) or stimulated with VEGF (50 ng/ml) or calcium ionophore (I0) (1 mM) for
the indicated times. Fractionated cytoplasmic or nuclear extracts were analyzed by Western blotting with the 67.1 antiserum for NFATp detection. The mobilities of
the upper and lower bands, corresponding to phosphorylated and dephosphorylated forms of NFATp, respectively, are indicated by arrows. (D) As a control for the
fractionation process, aliquots of the extracts used for NFATp detection were analyzed by Western blotting for the presence of nuclear PCNA. Cyt, cytoplasmic; V, VEGF.
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with the combination of PMA with calcium ionophore, a very
potent stimulus for NFAT activation in T lymphocytes, also
resulted in a strong increase in NFAT binding activity. In both
cases, the specific bands were competed with an excess of cold
oligonucleotide and CsA blocked the induction of NFAT
DNA-binding activity (Fig. 2A and data not shown). The iden-
tity of the nuclear factor(s) responsible for the retardation of
the DNA-protein complexes generated with the NFAT probe
was further characterized by EMSAs in the presence of anti-
NFAT antisera. These assays detected the sole presence of
NFATp (NFAT1) in the nuclear extracts of activated
HUVECs. Thus, the addition of specific anti-NFATp anti-
serum 67.1 (22) completely supershifted the NFAT complex
generated with nuclear extracts from HUVECs stimulated with
both VEGF and PMA plus ionophore. In addition, NFAT
complex formation was inhibited by incubation with the 796
anti-all-NFAT antiserum (33) directed against a conserved se-
quence among the NFAT proteins located in the DNA-binding
domain (Fig. 2B). We also performed control experiments by
analyzing the effect of VEGF and PMA plus ionophore on
NF-kB-binding activity by using aliquots of the nuclear extracts
where we detected induction of NFAT binding. These EMSAs
showed a clear induction of NF-kB in nuclear extracts from
HUVECs treated with PMA plus ionophore that was not af-
fected by CsA, whereas no substantial differences were found
in the binding to the NF-kB probe of cells treated or not with
VEGF for different periods (Fig. 2C).
VEGF activates NFAT and AP-1-dependent transcription
and increases c-fos and c-jun mRNA levels. NFAT has been
shown to cooperate with AP-1 transcription factor in transac-
tivation and DNA binding to mediate the transcriptional acti-
vation of a number of promoter elements (50). In addition,
signaling induced by VEGF results in the activation of MAPK
cascades that can integrate different signals at the AP-1 level
(5, 26). Therefore, we next analyzed whether AP-1 was a target
in the activation of VEGF that could cooperate with NFAT to
regulate VEGF-dependent transcription. For this purpose, we
first performed Northern blot experiments to determine the
effect of VEGF on the mRNA levels of c-fos and c-jun AP-1
components. As shown in Fig. 3A, c-fos mRNA steady-state
levels, undetected in untreated HUVECs, were induced after
30 min of treatment with VEGF. This induction was transient
and markedly declined after 1 h of activation (data not shown),
whereas stimulation with the phorbol ester PMA plus calcium
ionophore yielded a stronger induction of c-fos that peaked
after 1 h of stimulation and could be still detected after 4 h of
treatment. In contrast, c-jun mRNA levels were already de-
tected in unstimulated HUVECs, and VEGF induced a small
increase over the baseline mRNA levels by 30 min of activa-
tion. Parallel control experiments showed that c-jun mRNA
levels were strongly upregulated by PMA plus ionophore, dis-
playing similar kinetics to that exhibited by c-fos. The effect
of VEGF on AP-1 DNA binding activity was examined by
EMSAs, and a moderate increase in the DNA-binding activity
to an AP-1 site was reproducibly found when different nuclear
extracts from HUVECs treated with VEGF were used. The
complex generated with the AP-1 probe was supershifted in
the presence of anti-Fos and anti-Jun family antisera, and the
DNA binding was higher with extracts from cells stimulated
with PMA plus ionophore and was not inhibited by CsA (Fig.
3B and data not shown).
To further analyze the effect of VEGF on AP-1 activation,
FIG. 2. Kinetic analysis and serological characterization of the NFAT DNA-binding complexes induced by VEGF. Nuclear extracts from HUVECs stimulated for
the indicated times with VEGF (50 ng/ml) (V) or a combination of PMA (20 ng/ml) plus ionophore (1 mM) (P/I0) or pretreated with CsA (200 ng/ml) for 2 h before
stimulation were analyzed by EMSA. (A) Analysis of the DNA-binding activity to the NFAT probe of the IL-4 promoter in nuclear extracts from HUVECs activated
for different times with VEGF (VEGF or V). EMSAs with extracts from VEGF-activated cells pretreated with CsA as well as control extracts from PMA- plus
ionophore-treated cells are shown. The mobility of the specific VEGF-induced (CsA-sensitive) complex is indicated by an arrow. (B) Serological characterization of
the NFAT DNA-binding complexes. EMSAs were performed in the presence (1) or absence (2) of nuclear extracts from cells activated with VEGF or PMA plus
ionophore that were incubated with 0.5 ml of either preimmune serum (Preim.), anti-NFATp antiserum 67.1, or the anti-NFAT family antiserum 796 for 15 min prior
to the addition of the labeled probe. The VEGF-induced NFAT complex and the supershifted complexes induced by the anti-NFATp 67.1 are indicated by an arrow
and asterisks, respectively. (C) Nuclear extracts from HUVECs treated as in panel A were analyzed for NF-kB binding with the kB site of the IL-2 promoter as a probe.
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we carried out transfection experiments in HUVECs with the
273 Col Luc AP-1-dependent reporter plasmid. These exper-
iments revealed that both VEGF and PMA (included as a
positive control) stimulated the transcriptional activity of the
AP-1 reporter plasmid (Fig. 4A). Similar results were obtained
with a different AP-1-dependent construct driven by the rat
prolactin minimal promoter under the control of four TRE
tandem copies (data not shown). Given that the effects of
VEGF on translocation and DNA-binding activity of NFATp
were concomitant with the activation of AP-1, we next deter-
mined whether activation by VEGF resulted in the functional
activation of the distal NFAT motif of the IL-2 promoter, a site
that has been shown to require the binding of AP-1 and NFAT
to be functionally active (11, 50). Therefore, we transfected
HUVECs with a luciferase reporter construct driven by three
tandem copies of the NFAT–AP-1 composite site and found
that the transcriptional activity of this construct was signifi-
cantly induced in response to VEGF or PMA plus calcium
ionophore in a CsA-sensitive fashion (Fig. 4B).
Identification of an NFAT-binding site within the TF pro-
moter regulated by VEGF. To evaluate the functional rele-
vance of the activation of NFAT in the expression of endothe-
lial genes regulated by VEGF, we carried out a database search
for NFAT motifs within the promoters of several genes that
have been shown to be induced by VEGF. These analyses
revealed the presence of an NFAT consensus site at positions
2186 to 2194 within the TF promoter region (Fig. 5A). There-
fore, we next determined whether this site was able to bind
NFAT by performing EMSAs with synthetic oligonucleotides
spanning positions 2183 to 2197 of the TF promoter that
included the NFAT site. These experiments demonstrated the
ability of this site to efficiently bind NFAT from nuclear ex-
tracts of VEGF-treated HUVECs in a CsA-sensitive manner.
The specificity of this binding was further confirmed by addi-
tion of an excess of TF homologous oligonucleotide or an
excess of a heterologous oligonucleotide including the NFAT
site of the IL-4 promoter that abolished the specific binding to
the probe but not by the corresponding TF mut oligonucleo-
tide carrying several nucleotide substitutions within the NFAT
sequence that failed to compete the binding (Fig. 5). Further-
more, the addition of anti-NFATp or anti-all NFAT antisera
resulted in supershift or inhibition of the NFAT-DNA com-
plex, respectively (Fig. 5B).
Since the TF oligonucleotide from 2183 to 2197 included a
previously identified kB-like site reported to bind NF-kB in
response to TNF-a or LPS (34, 41, 51), we performed gel
retardation experiments with this TF probe and nuclear ex-
tracts from HUVECs treated with PMA plus ionophore, a
combination of stimuli that triggered the DNA-binding and
transcriptional activity of both NF-kB and NFAT (Fig. 2 and 4
and data not shown). Strikingly, as occurred with the complex
induced by VEGF, the inducible complex generated with nu-
clear extracts from HUVECs exposed to PMA plus ionophore
was supershifted by the anti-NFATp antiserum whereas no
supershift or inhibition of the binding was detected with anti-
sera directed against the p65 NF-kB subunit (Fig. 6). Parallel
control experiments with aliquots of the nuclear extracts of
cells activated with PMA plus ionophore and the prototypic kB
probe of the Igk light-chain enhancer revealed the presence of
an inducible NF-kB complex supershifted by the anti-p65 an-
tiserum (data not shown). Hence, the 2183 to 2197 region of
the TF promoter, including a previously identified kB site that
overlapped with the NFAT-binding site, bound exclusively to
NFAT from nuclear extracts of HUVECs activated by VEGF.
Similarly, the activation of these cells with PMA plus iono-
phore, which triggered both NFAT and NF-kB binding to
different consensus probes, induced predominant NFAT bind-
ing to the TF probe.
VEGF regulates TF gene expression by mechanisms involv-
ing NFAT in a CsA-sensitive fashion. Because of the presence
of the newly identified NFAT-binding site within the TF pro-
moter, we analyzed whether NFAT could play a role in the
regulation of TF gene expression induced by VEGF. We ini-
tially determined whether the induction described for TF pro-
tein in response to VEGF (9) was also reflected at the pro-
moter level. For this purpose, we transfected HUVECs with
the pL1 and pL4 plasmids containing the 22106 to 1121 and
the 2278 to 1121 upstream regulatory regions of the TF gene
FIG. 3. Effects of VEGF on the mRNA levels of c-fos and c-jun and on the DNA-binding activity of AP-1. (A) Northern blot analysis with total RNA from HUVECs
untreated or activated for the indicated times with VEGF or a combination of PMA plus ionophore (P/I0). After isolation, RNA was separated by agarose gel
electrophoresis, blotted onto a nitrocellulose membrane, and hybridized with specific probes for c-fos and c-jun. RNA controls of the corresponding blots are shown.
A sixfold-longer exposure of the autoradiograph is presented for the control and VEGF points of c-fos. (B) The AP-1 DNA-binding activity displayed by nuclear extracts
from HUVECs activated with VEGF or PMA plus ionophore (P/I0) for 1 h was tested with a specific probe encompassing the 2284 AP-1 site of the ICAM-1 promoter.
Extracts from CsA-treated cells were obtained after pretreatment of 2 h with 200 ng of CsA per ml and a further 1-h treatment with the stimuli. VEGF (50 ng/ml),
PMA (20 ng/ml), and A23187 calcium ionophore (1 mM) were used at the same doses in single or combined treatments in panels A and B.
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fused to the luciferase reporter gene, respectively (37). These
experiments showed that VEGF induced the transcriptional
activity of the TF promoter reporter plasmids by three- to
fivefold. This activation was lower than that displayed by PMA
plus ionophore, which appeared to be a very potent stimulus
for TF promoter activation, and was partially inhibited by CsA
(Fig. 7A and data not shown).
The involvement of NFAT in the regulation of TF promoter
by VEGF was analyzed in cotransfection experiments by test-
ing the effect of the expression of an NFAT dominant negative
plasmid (43) on the transcriptional activity of the pL4 TF
promoter reporter construct. As shown in Fig. 7B, the trans-
fection of the NFAT dominant negative expression construct
resulted in a clear although partial inhibition of the TF pro-
moter activity induced by VEGF or PMA plus ionophore.
Since the TF mut oligonucleotide carrying a 5-bp substitution
in the core region of the NFAT-binding site failed to compete
for the NFAT complex (Fig. 5B), we evaluated the functional
contribution of the identified NFAT site to the overall tran-
scriptional response of the TF promoter by performing site-
directed mutagenesis to introduce the same 5-bp substitution
into the pL4 TF reporter construct. Consistent with the results
of the cotransfection experiments with the NFAT dominant
FIG. 4. VEGF activates AP-1- and NFAT-dependent transcription- (A)
HUVECs were transfected by the calcium phosphate procedure with the AP-1-
responsive (273 to 163) region of the collagenase promoter plasmid for 4.5 h
and stimulated or left untreated for an additional 16 h, and then the luciferase
activity was determined. The data is expressed as the mean and standard devi-
ation (error bars) of determinations performed in triplicate. Results of a repre-
sentative experiment are shown. Four different experiments yielded similar re-
sults. (B) HUVECs were transfected with an NFAT-dependent luciferase
reporter plasmid. At 16 h after transfection, the cells were pretreated or not (2)
with CsA (200 ng/ml) for 2 h, and then left untreated or further stimulated for
an additional 6 h with VEGF or a combination of PMA and calcium ionophore
(P/I0). The results are expressed as the relative fold induction over the relative
luciferase units (RLU) displayed by the corresponding transfected unstimulated
cells. Results of a representative experiment of five are shown. VEGF (50 ng/ml),
PMA (20 ng/ml), and A23187 calcium ionophore (1 mM) were used at the same
doses in single or combined treatments in panels A and B.
FIG. 5. NFATp binds to the 2183 to 2197 region within the TF promoter.
(A) The sequences (59 to 39) of the oligonucleotides including the 2183 to 2197
region of the TF promoter (TF wt) and that of the TF mut are shown. Base pair
substitutions incorporated in the TF mut are indicated by asterisks. The partially
overlapping nucleotides corresponding to the kB-like and the NFAT sites are
indicated. (B) Nuclear extracts from HUVECs pretreated or not with 200 ng of
CsA per ml and then exposed to VEGF (50 ng/ml) were analyzed by EMSA with
a probe spanning positions 2183 to 2197 of the TF promoter. A 30-fold molar
excess of unlabeled TF 2183 to 2197, the corresponding oligonucleotide mu-
tated at positions 2186 to 2194 (TF mut), or an NFAT consensus site of the IL-4
promoter oligonucleotides was added to the binding-reaction mixtures to detect
the specific binding. Serological identification of the complexes was performed
by addition of 0.5 ml of either preimmune serum (Preim.), anti-NFATp anti-
serum (67.1), or anti-NFAT family antiserum (796). Antisera and cold oligonu-
cleotides were added to the binding-reaction mixture prior to addition of the
probe.
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negative construct and the TF promoter, the inducibility of the
mutated TF promoter was significantly reduced in response to
both VEGF and PMA plus ionophore (Fig. 8A).
To analyze whether the effects exerted by VEGF on the
activation of TF at the promoter level correlated with those
detected on the TF mRNA steady-state levels, we performed
Northern blot experiments of HUVECs exposed to VEGF or
PMA plus ionophore in the presence or absence of CsA. These
experiments revealed that TF mRNA levels, undetected in
resting HUVECs, were upregulated after treatment with
VEGF or PMA plus ionophore. Exposure of cells to VEGF
resulted in maximal expression of TF mRNA after 1 h of
treatment and a progressive decline between 4 and 8 h. Fur-
thermore, the induction of TF mRNA levels induced by both
VEGF and PMA plus ionophore was markedly inhibited by
CsA at the different time points analyzed (Fig. 8B).
Taken together, these results suggest that VEGF regulates
TF gene expression in endothelial cells by transcriptional
mechanisms involving the activation of NFAT, and they iden-
tify a functional NFAT site required for full inducibility of the
TF promoter that is likely to account for the partial inhibition
of TF gene expression displayed by CsA.
DISCUSSION
VEGF is a multifunctional cytokine that plays a pivotal role
in the regulation of angiogenesis and is required for the de-
velopment and differentiation of the vascular system (6, 18).
Despite extensive research focused on the biological functions
of VEGF and its role in the physiological and pathological
angiogenic processes, the molecular mechanisms of signal
transduction and the transcription factors that couple such
signals to the gene expression programs induced by VEGF are
still largely unknown. In this study, we show that VEGF trig-
gers the activation of NFAT and AP-1, two transcription fac-
tors that are rapidly mobilized in cell activation processes to
regulate gene transcription in response to a large number of
stimuli (26, 51). To our knowledge, this is the first report
demonstrating the activation of NFAT by a physiological stim-
ulus in endothelial cells. In addition, we have found that the
VEGF-induced expression of TF involves the activation of
NFAT and identified a functional NFAT-binding site within
the TF promoter that overlaps with a previously identified
kB-like element.
Exposure of HUVECs to VEGF increases the intracellular
FIG. 6. Serological analysis of the binding to the TF/NFAT site induced by
VEGF and PMA plus ionophore. The DNA binding to the 2183 to 2197 region
of the TF promoter was analyzed by using nuclear extracts from HUVECs
treated with VEGF (50 ng/ml) or with PMA (20 ng/ml) plus A23187 calcium
ionophore (1 mM) for 1 h. Anti-NFATp antiserum 67.1 (0.5 ml) or 1 ml of
anti-p65 antisera was added to the binding-reaction mixture before the addition
of the probe.
FIG. 7. Effects of CsA and NFAT dominant negative plasmid on the tran-
scription of the TF promoter by VEGF. (A) The transcriptional activity of the TF
promoter was tested by transfection of HUVECs. The pL4 and pL1 luciferase
reporter plasmids (10 mg) were transfected by calcium phosphate precipitation
for 4.5 h. At 16 h posttransfection, cells were preincubated or not (2) with CsA
for 2 h, and further stimulated for 6 h with VEGF, PMA plus ionophore (P/I0),
or vehicle. Results of a representative experiment of three independent experi-
ments performed are shown. (B) The pL4 promoter construct (5 mg) was co-
transfected with 5 mg of either the NFAT dominant negative pSH102CD418
expression vector or its parental empty vector (pBJ5). At 16 h after transfection,
the cells were stimulated with VEGF, PMA plus ionophore (P/I0), or vehicle for
6 h. Results of a representative experiment of three independent ones are
presented. The results are expressed as fold induction over the expression of pL4
and pL1 plasmids in the absence of stimuli in both panels. Experiments were
performed in triplicate. VEGF (50 ng/ml), PMA (20 ng/ml), CsA (200 ng/ml),
and A23187 calcium ionophore (1 mM) were used at the same doses in single and
combined treatments.
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calcium concentration (12, 45). In T lymphocytes and fibro-
blasts, elevations of intracellular calcium levels result in cal-
cineurin activation and subsequent activation and nuclear lo-
calization of NFAT proteins (32, 54, 59, 60). Similarly, we have
demonstrated that the dephosphorylation and translocation of
NFATp triggered by both VEGF and calcium ionophore were
blocked by the calcineurin inhibitor CsA in endothelial cells.
Once in the nucleus, the imported NFAT was detected dis-
playing forms with the mobility of phosphorylated NFATp at
times when the transcription factor was progressively found in
the cytoplasm of activated cells, and this process was indepen-
dent of RNA synthesis. These data suggest that the activation
of the calcium-calcineurin pathway in HUVECs by VEGF
leads to the translocation of NFATp to the nucleus, where it is
phosphorylated and then exported to the cytoplasm. There-
fore, NFATp activation appears to be regulated in HUVECs
by mechanisms similar to those operating in T cells or fibro-
blasts.
The major role that endothelial cells play in angiogenesis as
well as in inflammatory and immune reactions is mediated
largely by its ability to produce and respond to cytokines (38).
In a previous report, NFATp has been shown to be activated in
endothelial cells treated with PMA plus calcium ionophore
and bind to an NFAT site of the GM-CSF enhancer. Further-
more, in these activated cells, the induction of both the tran-
scriptional activity of a GM-CSF enhancer-promoter reporter
construct and protein synthesis of GM-CSF were partially in-
hibited by CsA (10). Although NFAT proteins are the major
targets of the calcineurin inhibitors CsA and FK506, these
drugs have been shown to affect the activation of other tran-
scription factors that can also be regulated by calcineurin (23,
25, 61, 66). Since the expression of other cytokines produced by
endothelial cells including IL-1, IL-6, and IL-8 is inhibited by
CsA in different cell types (51), the possible involvement of
NFAT in the transcriptional regulation of these cytokine genes
in endothelial cells will be an important issue for future stud-
ies.
We have detected by serological analysis of the NFAT-bind-
ing complex generated with nuclear extracts from HUVECs
activated with VEGF the presence of only the NFAT1
(NFATp) protein. Likewise, NFATp was the only member
detected in the DNA-binding complexes formed with the GM-
CSF probe in endothelial cells activated with PMA plus iono-
phore (10). Hence, of the four NFAT family members identi-
fied, only NFATp protein has so far been found to be
expressed by endothelial cells in the adult. However, using
specific oligonucleotides of the different members, as well as
degenerate oligonucleotides of sequences within the DNA-
binding domain of NFAT members, we have amplified by
reverse transcription-PCR the cDNAs of NFAT1 (NFATp),
NFAT2 (NFATc), NFAT3, and NFATx from mRNA of
HUVECs (data not shown). Although the presence of mRNAs
of the different forms does not imply the presence or the
functional involvement of these proteins, if other NFAT pro-
teins are actually expressed in these endothelial cells, they
could be potentially involved in the regulation of TF or GM-
CSF gene expression by other stimuli or in the control of other,
so far unidentified, NFAT-regulated endothelial genes. In this
regard, it is important to note the recent identification of
NFATc in endocardial cells during embryonic heart develop-
ment, where it has been found to be required for the formation
of the aortic and pulmonary valves (13, 49). Endocardial cells
are specialized endothelial cells of the heart that give rise to
the cardiac valves and septum. It is noteworthy that the trans-
location of NFATc to the nucleus of these cells can be inhib-
ited by CsA or FK506 in cultured whole embryos (13, 49),
suggesting the involvement of the calcium-calcineurin signaling
pathway in the morphogenesis of cardiac valves and septum.
Since the ligand(s) that triggers the translocation of NFATc in
endocardial cells during development has not so far been iden-
tified, it will be important to determine whether VEGF could
play a role in this important process.
The effects of VEGF activating pathways that involve the
MAPKs ERKs (12, 53, 56), JNKs/SAPKs (30), and p38/HOG
(53) in endothelial cells are consistent with the activation of
AP-1 by VEGF that we show here. These MAPKs are compo-
nents of the signal transduction cascades that regulate the
AP-1 family members at the transcriptional and posttranscrip-
tional levels (20, 26). Although we observed a clear induction
of the human collagenase AP-1-dependent reporter construct
and the mRNA levels of c-fos, both the AP-1 DNA-binding
activity and the c-jun mRNA levels were only weakly induced
in response to VEGF. The lack of correlation between AP-1
DNA-binding and transcriptional activation has been previ-
ously noted in other cell systems, and the reason for this dis-
agreement appears to be related to the changes in the compo-
sition of the AP-1 complexes during the activation processes.
Thus, various members of the Fos family can associate with
FIG. 8. Inhibition of VEGF-induced TF expression by CsA. (A) HUVECs were transfected by calcium phosphate precipitation with 10 mg of the parental pL4
luciferase plasmid or with the pL4mut-derived plasmid mutated in the NFAT site for 4.5 h. At 16 h posttransfection, the cells were stimulated for 6 h with VEGF (50
ng/ml) or PMA (20 ng/ml) plus ionophore (1 mM). Experiments were performed in triplicate, and the results are expressed as fold induction over the baseline levels
of transfected unstimulated cells. Results of a representative experiment of three performed are shown. (B) Northern blot analysis of HUVECs pretreated or not (2)
with CsA (200 ng/ml) for 2 h and further stimulated with VEGF (50 ng/ml) or a combination of PMA (20 ng/ml) plus ionophore (1 mM) (P/I0) for the time points
indicated. Total RNA was electrophoresed, blotted onto a nitrocellulose membrane, and hybridized with a TF cDNA probe. Autoradiographs corresponding to
exposures for VEGF and PMA-plus-ionophore treatments of 1 week and 16 h, respectively, and RNA controls of the blot are presented.
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Jun proteins to form heterodimers displaying similar DNA-
binding activities but different transactivating capabilities. In
addition, the phosphorylation of Fos and Jun proteins has been
reported to stimulate their transactivating efficacy without al-
tering the DNA-binding activities (14, 26). The effect of VEGF
on the activation of AP-1 is evidenced not only by the stimu-
lation of transcriptional activity of the AP-1 dependent re-
porter construct 273 Col Luc but also by the activation exerted
on the reporter construct directed by the NFAT–AP-1 com-
posite site of the IL-2 promoter, whose transcriptional induc-
tion requires the activation of both NFAT and AP-1 transcrip-
tion factors (47). Furthermore, we have confirmed the
involvement of the AP-1 transcription factor in the VEGF-
mediated endothelial activation by using the TAM-67 c-jun
dominant negative plasmid, whose expression basically blocked
the transcriptional activity of the TF promoter in response to
VEGF (data not shown). Whether this blocking effect of
TAM-67 reflects the relevance of the AP-1-binding sites of the
promoter in response to VEGF or the importance of cooper-
ative interactions of AP-1 with other transcription factors (or
both) remains to be determined.
TF deficiency results in embryonic death due to defective
yolk sac vessel and abnormal vitelloembryonic circulation (7).
Since the abnormal yolk sac vasculature resembles in part the
phenotype found in VEGF-deficient embryos (6, 18), the pos-
sibility that the functions of VEGF and TF are interrelated has
been suggested (8). In fact, the induction of TF by VEGF leads
to the generation of fibrin and the sequential activation of tPA
and plasmin, which stimulates the degradation of matrix pro-
teins, a critical step for the migration and sprouting of endo-
thelial cells during angiogenesis (57). Experiments aimed to
establish a functional link between VEGF-induced gene ex-
pression and the activation of NFAT and AP-1 transcription
factors led us to analyze the TF gene promoter. TF expression
in monocytes and endothelial cells is induced by a variety of
proinflammatory agents, including LPS, IL-1b, and TNF-a,
through transcriptional and posttranscriptional mechanisms
(34). Previous reports have identified Sp1–Egr-1 sites required
for basal expression of the gene and NFkB and AP-1 sites
involved in the inducible response to LPS and cytokines, and a
concerted action of the transcription factors that bind to these
sites has been proposed to regulate TF promoter in monocytes
and endothelial cells (34, 36, 41, 44). We have shown that
VEGF induced the expression of TF mRNA levels and the
transcriptional activation of the TF gene promoter involving
the activation of NFAT. This role of NFAT was evidenced by
the expression of the NFAT dominant negative construct that
resulted in significant inhibition of the TF promoter transcrip-
tion by VEGF, and it correlated with the defective inducibility
displayed by the TF promoter construct carrying the NFAT
mutated site. In both cases, the inhibitory effect observed was
partial, as occurred with that displayed by CsA on both the TF
promoter activation and mRNA expression triggered by
VEGF. Since we have also demonstrated that the effects of
CsA precluding the translocation and transcriptional activation
of NFAT are also operative in VEGF-activated endothelial
cells, these data suggest that the inhibition of TF gene expres-
sion by CsA is exerted through the inhibition of NFAT acti-
vation. Given the role that AP-1 appears to play in the activa-
tion of TF promoter, it is likely that AP-1 could account for the
promoter activity that was refractory to the inhibition by CsA
or to the expression of the NFAT dominant negative construct.
The presence of an NFAT site overlapping with a previously
identified kB-like functional site within the TF promoter is
noteworthy. Since previous studies have demonstrated the abil-
ity of this site to bind NF-kB proteins in response to LPS or
TNF-a (34, 41, 44), our data indicate that the NFAT–NF-kB
motif (CGGAGTTTCCT) may represent one example of the
kB-like sites such as those of the CD28RE of the IL-2 and
GM-CSF promoters, which also include the TTCC sequence,
thought to be critical for the binding of either NFAT or NF-kB
proteins but not both simultaneously (51). However, stimula-
tion of HUVECs with PMA plus ionophore, which resulted in
the activation of NF-kB-binding activity to the IL-2 or Igk
light-chain kB probes, strongly stimulated NFAT binding to
the TF probe but failed to induce detectable kB binding activ-
ity to this probe. Therefore, NFAT binding to this NFAT–
NF-kB motif appears to be predominant (or exclusive) when
cells are activated by a stimulus that triggers the simultaneous
activation of NFAT and NF-kB. The comparative analysis of
the murine, porcine, and human sequences of the TF promoter
(41) revealed that the NFAT sequence (GAGTTTCCT) is
completely conserved in all three species whereas the partially
overlapping NF-kB sequence ([C/T]GGAGTTTCC) displays a
9-of-10-base match among the species. The high degree of
conservation of this region is consistent with the critical role
reported in the regulation of the TF gene by proinflammatory
stimuli through NF-kB (34) and also with its functional role in
the response to VEGF or other stimuli that could induce the
TF gene by triggering the activation of NFAT.
The inhibition of TF gene expression by CsA that we have
detected suggests a putative role of this drug interfering with
the procoagulant activity of VEGF described in monocytes and
endothelial cells (9). CsA has also been reported to reduce the
activation of TF transcription and NF-kB-binding activity to
the TF-kB site in LPS-activated monocytes as well as in mono-
cytes from cardiac transplant recipients (23, 24). TF is thought
to be involved in fibrin deposition and thrombogenic processes
associated with a number of disorders, including atherosclero-
sis, septic shock, and cancer (34, 52). Therefore, it is conceiv-
able that part of the beneficial effects described for CsA in
some of these clinical disorders, such as those reported for
experimental transplant atherosclerosis (2), are related not
only to the reported ability of the drug to interfere with the
activation of TF expression by stimuli that trigger NFkB acti-
vation but also to those that induce NFAT activation in non-
lymphoid cells such as VEGF. On the other hand, given the
major role of VEGF in physiological and pathological angio-
genesis, the identification of NFAT and AP-1 as transcription
factors that couple VEGF signaling to the transcriptional gene
response may help to localize therapeutic targets to antagonize
or modulate the angiogenic process and to further delineate
the upstream signaling pathways and the specific gene expres-
sion program triggered by VEGF in endothelial cells.
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